All
How not to get involved in an Internet "flame" war
April 1st 2002As Internet authority Steve Litt has noted: Never get personal. Never say "you're an idiot" or "you're a hypocrite," and try to avoid saying "you're wrong." No matter how true the statement, it's almost guaranteed to generate a heavy-handed response that will just draw you into a potentially dangerous and unprofitable conflict.
Post-Sept. 11 attitudes reflected on dermatologists
April 1st 2002If money grew on trees, if Sept. 11 and the recession hadn't happened, and if the federal budget wasn't in deficit once again, dermatologists and other physicians might see last year's 5.4 percent Medicare payment cut rescinded by a generally sympathetic Congress
Cosmetic Conundrum with Zoe Diana Draelos, MD
April 1st 2002Q. What is the benefit of the new facial cleansing cloths?A. The newest way to clean the face is use of a disposable single-use cleansing cloth impregnated with a cleanser. These cloths are made in two varieties for normal to oily skin and normal to dry skin, with designs particular to each ailment.
Cosmetic Conundrums with Zoe Diana Draelos, M.D.
March 2nd 2002Q. What factors determine the SPF performance of a given sunscreen?A. The SPF is the sun protection factor afforded by a given sunscreen. It is determined by dividing the lower back of untanned individuals is into small test sites which are exposed to UVB light until a minimum amount of erythema develops, known as the MED. Lightproof barriers are placed around the test sites to prevent light contamination from one test site to another. Once the MED for the test subject has been determined, the subject is invited to return to the test site the next day for application of sunscreen. The sunscreen is placed on the test sites and allowed to dry. The skin is then exposed to UVB light at the expected SPF of the sunscreen product. The expected SPF is roughly determined by spectrophotometric absorption. The amount of UVB light required to obtain the same degree of erythema as the preceding day is determined and the SPF calculated.
Alefacept valuable against psoriatic arthritis
March 2nd 2002New Orleans - Results from a single-center pilot study indicatethat I.V. alefacept (Amevive), the human LFA3-IgG1 fusion protein, may safelyand effectively improve the skin and joint manifestations of psoriatic arthritis,researchers from the Academic Medical Center, University of Amsterdam, TheNetherlands, reported at the annual meeting of the American Academy of Dermatology.
She is not 18; can she provide informed consent?
March 2nd 2002Jane, a very mature 17-year-old adolescent, presents to Dr. Jones forremoval of a facial nevus. Dr. Jones discusses the risk/benefit ratio ofsuch an excision. In the course of the discussion, he determines that sheis working a full-time job and lives with her boyfriend at home with herparents. She signs a standard consent form. Dr. Jones does not realize thatshe is 17; he did not ask. Ultimately she is not happy with the scar andwishes to sue her dermatologist. The basis of her suit is that at age 17she was not able to provide informed consent. Dr. Jones is aware that, asa general rule, a patient must be 18 years of age to provide informed consent.However, he contends that Jane was highly intelligent, articulate and hada better understanding of the procedure than some 19 year olds might have.Can Jane, as an adolescent, give informed consent?
Hemangioma observations illuminate variations
March 1st 2002New Orleans - Although the natural history and imaging characteristics of hemangiomas are well known, some new or relatively new observations have led to further sub-categorization, Patricia E. Burrows, M.D., said at the 60th annual meeting of the American Academy of Dermatology.
Infliximab dramatically clears severe psoriasis
March 1st 2002New Orleans - The experience of a teenage girl treated successfully with infliximab (Remicade) for severe, recalcitrant psoriasis of her hands and feet indicates the value of the TNF-alpha chimeric monoclonal antibody as a therapeutic option for psoriasis.
Topical tacrolimus improves vitiligo; adding sunlight may help even more
March 1st 2002New Orleans - Results from an exploratory study indicate a potential role for topical tacrolimus in the management of vitiligo, Emil A. Tanghetti, M.D., said at the annual meeting of the American Academy of Dermatology.
Calcium alginate dressing closes cancer defects
March 1st 2002New Orleans - Second intention healing with a calcium alginate dressing can be a useful alternative for closing skin-cancer excision facial defects in select patients who might otherwise be managed with primary closure, local flaps, or skin grafts, Roger H. Weenig, M.D., M.P.H., said at the annual meeting of the American Academy of Dermatology.
Anticonvulsant additive reduces herpetic pain
March 1st 2002New Orleans - Data from an open-label study suggest that the anticonvulsant drug gabapentin (Neurontin) added to antiviral treatment during acute herpes zoster infection may further reduce the duration and severity of postherpetic neuralgia, Mathijs H. Brentjens, M.S., M.D., reported at the annual meeting of the American Academy of Dermatology.
Hemangiomas, malformations continue to evolve in definition
March 1st 2002New Orleans - Just like the endothelial cells that proliferateand produce hemangiomas, the field of study that surrounds these benigntumors of infancy and childhood continues to be a work in progress, MoiseL. Levy, M.D., said at the 60th annual meeting of the American Academy ofDermatology.
The human genome: Applying it to practice
March 1st 2002Miami Beach, Fla. - Dermatologists and pediatricians often areafraid of learning the technicalities of the human genome. However, onlya basic knowledge, an understanding of how genetics might apply to practice,and a relationship with a geneticist who can answer your questions are necessaryto use the tools available today, Judith G. Hall, O.C., M.D., said.
Derms divulge how they have such flawless skin
March 1st 2002* Never use the same product year-round. "Because skin isa living organ that's constantly affected by everything from hormones tohumidity, I use a variety of products - some only in certain seasons andothers just on certain days," says Susan Taylor, M.D., director, Skinof Color Center at St. Luke's Roosevelt Hospital, New York.
Oritavancin shortens treatment time for complicated skin-structure infections
March 1st 2002Chicago - Oritavancin (InterMune), an investigational glycopeptidewith activity against a wide range of Gram-positive pathogens, has beenshown to cut the treatment time in half for complicated skin and skin structureinfections (CSSIs) compared to current standard therapy with vancomycinplus cephalexin, Margaret Wasilewski, M.D., said at the 41st InterscienceConference on Antimicrobial Agents & Chemotherapy.
Patients rights bill: A new political football?
March 1st 2002Lobbyists for insurance companies, the managed care industry, and dozensof large trade associations are worried. Their old buddy, PresidentBush, has been talking to one of their biggest enemies, Sen. Ted Kennedy(D-MA), about, heaven forbid, managed care reform.